Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
9,154people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
SGLT2-i
placebo
Lowered long-term blood sugar−0.69
randomisedThe trial randomly assignedassigned by chance
Canagliflozin
placebo
Lowered long-term blood sugar−0.85
randomisedthe abstract, start to end
… compared with placebo (mean difference -0.69%, 95% confidence interval -0.75 …
… with the largest reduction in HbA1c (-0.85%, -0.99% to -0.71%).
… of SGLT2-i on HbA1c compared with OAD (-0.20%, -0.28 to -0.13%; moderate …
← favours treatmentfavours comparator →
could be chanceHbA1cSGLT2-i vs placebo
−0.69−0.75 to −0.62
HbA1cCanagliflozin vs placebo
−0.85−0.99 to −0.71
HbA1cSGLT2-i vs OAD
−0.20−0.28 to −0.13
SGLT2 inhibitorsGlycemic control
SGLT2 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.92not counted
← favours treatmentfavours comparator →
1 / 7